One Shot, Six Years, No Cancer

A personalized mRNA vaccine kept 11 of 14 breast cancer patients relapse-free for six years, no boosters needed

25 Mar 2026

A personalised mRNA vaccine developed by BioNTech and the University Medical Centre Mainz kept the majority of patients with early-stage triple-negative breast cancer free of recurrence for up to six years, according to research published in Nature in February 2026.

Of the 14 patients enrolled in the trial, 11 remained cancer-free throughout the follow-up period. Immune responses generated by the vaccine persisted without booster doses, a finding researchers described as particularly significant.

Each patient's vaccine was engineered individually, encoding up to 20 tumour-specific mutations identified by sequencing tissue removed during surgery. The mutation sequences were delivered intravenously via lipid nanoparticles. Scientists identified two populations of vaccine-activated immune cells: one designed to act immediately against tumour cells, and a second that functions as long-term immune memory, remaining active for years after initial treatment.

Triple-negative breast cancer, which accounts for roughly 15 per cent of all breast cancer diagnoses, carries high recurrence rates and has fewer targeted treatment options than other subtypes. Durable disease control in this group has historically been difficult to achieve, making the trial's six-year outcomes notable even at small scale.

BioNTech, based in Mainz, has built one of the most advanced personalised cancer vaccine programmes in the industry. The Mainz trial, alongside ongoing Phase II studies in pancreatic and colorectal cancers, reflects a broader shift in European mRNA research away from infectious disease and toward individually tailored cancer therapies.

Researchers caution that the study was small and exploratory, and that larger controlled trials are needed before conclusions about survival benefit can be drawn. The cost and time required to manufacture a bespoke vaccine for each patient remain practical barriers to wider use. Advances in artificial intelligence-assisted target identification and automated production are compressing timelines across the sector, though the pace at which those gains translate into accessible treatments remains unclear.